Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01835236
Other study ID # SAKK 22/10
Secondary ID 2012-002556-17UN
Status Completed
Phase Phase 2
First received
Last updated
Start date March 3, 2013
Est. completion date May 26, 2020

Study information

Verified date March 2021
Source Swiss Group for Clinical Cancer Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In HER2-positive metastatic breast cancer, trastuzumab based treatment is the standard of care as long as there are no contraindications to trastuzumab. Frequently, trastuzumab is being combined with taxanes in the first-line setting. However, since therapy with trastuzumab is active even in the absence of chemotherapy in HER2-positive MBC, the optimal treatment strategy either in combination or in sequence with chemotherapy is still under debate. This randomized phase II trial is studying a new strategy for the treatment of metastatic breast cancer with HER2-positive. First-line treatment consists of trastuzumab and pertuzumab, a treatment without chemotherapy. In case of disease progression, chemotherapy with T-DM1 is then performed as second-line treatment. Third-line and further line therapies are performed according to the physician's discretion. If this new therapeutic strategy is as effective and better tolerated than the conventional strategy, this would mean a serious breakthrough in the treatment of HER2-positive metastatic breast cancer.


Description:

OBJECTIVES: Primary -To evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) and of a chemotherapy-containing dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) in patients with HER2-positive metastatic breast cancer. Secondary - To evaluate other efficacy parameter - To evaluate the safety and tolerability profile of the two treatment strategies - To evaluate the Quality of Life (QoL) - To learn how patients are treated after trial treatment OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor status (positive vs negative), prior trastuzumab (never or >12 months vs ≤12 months after last infusion), visceral metastases (present vs absent) and site. Patients are randomized to 1 of 2 treatment arms.


Recruitment information / eligibility

Status Completed
Enrollment 208
Est. completion date May 26, 2020
Est. primary completion date January 11, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility SELECTION OF PATIENTS (MOST IMPORTANT CRITERIA) Inclusion criteria for first-line therapy • Histologically confirmed breast cancer with distant metastases Note: 1. A biopsy from the primary tumor or a metastasis can be used for diagnosis. 2. Patients with non-measurable lesions are eligible. 3. Patients with inoperable, locally advanced breast cancer with lymph node metastases other than ipsilateral locoregional (axillary, infraclavicular, parasternal) or other distant metastases are eligible. 4. Patients with bone metastases with or without bone targeted therapy (bisphosphonates, denosumab) are eligible. 5. Patients with de-novo Stage IV disease are eligible. - HER2-positive tumor according to central pathology testing for HER2 Note: 1. A formalin-fixed paraffin-embedded (FFPE) biopsy from the primary tumor or a metastasis has to be used for HER2 status determination. If a biopsy is available from a metastasis, the HER2 testing should be performed using the metastasis. 2. Fine needle aspiration is not acceptable for HER 2 testing. • Women aged =18 years • WHO performance status 0 to 2 - Left Ventricular Ejection Fraction (LVEF) =50% as determined by either ECHO or MUGA - Adequate organ function, evidenced by the following laboratory results: Neutrophils >1.5x109/L, platelets >100x109/L, hemoglobin =90g/L, total bilirubin =1.5xULN (unless the patients has documented Gilbert's disease), AST =3xULN, ALT =3xULN, AP =2.5xULN (except in patients with bone metastases: AP =5xULN), creatinine =1.5xULN Exclusion criteria for first-line therapy • Prior chemotherapy for inoperable locally advanced or metastatic breast cancer Note: Prior neoadjuvant/adjuvant chemotherapy is allowed if doses for anthracyclines have not exceeded 720mg/m2 and 240mg/m2 for epirubicin and doxorubicin, respectively. - Re-exposure to paclitaxel is permitted, if the last dose of taxane was given at least 1 year before randomization. - Re-exposure to vinorelbine is permitted, if the last dose of vinorelbine was given at least 1 year before randomization. - Prior anti-HER2 treatment for metastatic or inoperable breast cancer Note: Prior neoadjuvant/adjuvant anti-HER2 treatment with trastuzumab and/or lapatinib is allowed. • More than one endocrine treatment line for metastatic or inoperable breast cancer exceeding a duration of 1 month Note: 1. Adjuvant endocrine treatment is not counted as one line. 2. Patients progressing on endocrine treatment: this specific endocrine treatment must have been stopped at least 2 weeks prior to randomization. • Prior treatment with pertuzumab and/or T-DM1 • Known leptomeningeal or CNS metastases Note: A brain MRI or CT scan is mandatory in case of clinical suspicion of CNS metastases. • Single bone metastasis treated with radiotherapy (if the bone metastasis is the only tumor lesion) Inclusion criteria for second-line therapy • At least one dose of trial therapy in the first-line treatment phase of this trial • • Proven disease progression on first-line therapy or radiotherapy of a bone metastasis Notes: First new parenchymal CNS metastases only do not count as progression requiring the initiation of second line trial treatment. Radiotherapy of a single area only for pain control is allowed and will not count as PD. • Adequate organ function, evidenced by the following laboratory results: Neutrophils >1.5x109/L, platelets >100x109/L, hemoglobin =90g/L, total bilirubin =1.5xULN (unless the patients has documented Gilbert's disease), AST =3xULN, AP =2.5xULN (except in patients with bone metastases: AP =5xULN), creatinine =1.5ULN • LVEF =50% as determined by either ECHO or MUGA • QoL questionnaire has been completed. Exclusion criteria for second-line therapy • Termination of first-line therapy with trastuzumab/pertuzumab due to unacceptable toxicity without objective evidence of disease progression • CNS metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as a history of radiation, surgery, or other therapy, including steroids, to control symptoms from CNS metastases within 2 months (60 days) before registration • Peripheral neuropathy of CTCAE grade =3 - Interstitial lung disease (ILD) or pneumonitis grade =3 - Any other adverse event which has not recovered to CTCAE grade =1 (except alopecia)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Trastuzumab
First administration (loading dose) 8 mg/kg i.v. infusion over 90 min. - then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.
Pertuzumab
First administration (loading dose) 840 mg i.v. infusion over 60 min. - then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.
Paclitaxel
Day 1, 8 and 15; every 4 weeks for =4 months 90 mg/m2 i.v. infusion
Vinorelbine
First administration: Day 1 and 8 25 mg/m2 i.v. infusion then day 1 and 8, every 3 weeks for =4 months 30 mg/m2 i.v. infusion
T-DM1
Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)

Locations

Country Name City State
France Hopital Sud - Amiens Amiens
France ICO - Paul Papin Angers
France Institut Sainte Catherine Avignon Cedex 9
France Centre Hospitalier de Blois Blois
France Institut Bergonie Bordeaux
France Hôpital Morvan (Brest) Brest
France Centre Francois Baclesse Caen
France Centre Hospitalier Alpes Leman Contamine-Sur-Arve
France Centre Georges François Leclerc Dijon Cedex
France Centre Hospitalier de Dracenie Draguignan
France Hopital Michallon - Centre Hospitalier Universitaire de Grenoble Grenoble
France Clinique Hartmann Levallois-Perret
France Centre Oscar Lambret Lille
France Chu de Limoges - Hopital Dupuytren Limoges
France Centre Hospitalier - Site Hopital du Scorff Lorient Cedex
France Clinique de la Sauvegarde Lyon
France Fondation Hopital Ambroise Pare - Hopital Europeen Marseille
France Istitut Paoli Calmettes Marseille
France Institut Regional du Cancer Montpellier Val d'Aurelle Montpellier
France Centre Azureen de Cancerologie Mougins
France Polyclinique de Gentilly Nancy
France Centre Catherine de Sienne Nantes
France Centre Antoine Lacassagne Nice Cedex 2
France Hopital Saint Louis Paris
France Centre Hospitalier de Pau Pau
France Centre Hospitalier de Perpignan - Hopital Saint Jean Perpignan
France Institut Jean Godinot Reims
France Centre Henri Becquerel Rouen
France Clinique Mathilde Rouen
France ICO - Rene Gauducheau Saint Herblain
France Curie Site Saint-Cloud Saint-Cloud
France Institut de Cancerologie de la Loire Saint-Priest-En-Jarez
France Hopitaux Universitaire de Strasbourg - Hopital Civil Strasbourg
France Hopitaux du Leman - Site Georges Pianta Thonon Les Bains
France Institut Claudius Regaud Toulouse Cedex 9
France Centre Hospitalier de Valence Valence Cedex 9
Germany Universitäts-Frauenklinik Ulm Ulm
Netherlands Almelo_Ziekenhuisgroep Twente Almelo
Netherlands Antoni van Leeuwenhoek / Slotervaart hospital Amsterdam
Netherlands VUmc University Medical Center Amsterdam
Netherlands Reinier de Graaf Gasthuis Delft
Netherlands Haga Ziekenhuis Den Haag
Netherlands Deventer Ziekenhuis Deventer
Netherlands Catharina Ziekenhuis Eindhoven
Netherlands Medisch Centrum Leeuwarden Leeuwarden
Netherlands Leiden_Leids Universitair Medisch Centrum (LUMC) Leiden
Netherlands St. Antonius Ziekenhuis, Ioc Nieuwegein Nieuwegein
Netherlands St. Franciscus Gasthuis Rotterdam Rotterdam
Netherlands Vlietland Ziekenhuis Schiedam
Netherlands Orbis Medisch Centrum Sittard
Switzerland Hirslanden Klinik Aarau Aarau
Switzerland Kantonspital Aarau Aarau
Switzerland Kantonsspital Baden Baden
Switzerland Universitaetsspital-Basel Basel
Switzerland Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli Bellinzona
Switzerland Inselspital, Bern Bern
Switzerland RSV-GNW Spitalzentrum Oberwallis Brig
Switzerland Spitalzentrum Oberwallis Brig
Switzerland Kantonsspital Graubuenden Chur
Switzerland Kantonsspital Frauenfeld / Brustzentrum Thurgau Frauenfeld
Switzerland Hopitaux Universitaires de Geneve Genève 14
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne
Switzerland Centre Hospitalier Universitaire Vaudois CHUV Lausanne
Switzerland Kantonsspital Liestal Liestal
Switzerland Kantonsspital Luzern Luzerne
Switzerland Kantonsspital Olten Olten
Switzerland Kantonsspital St. Gallen St. Gallen
Switzerland Zentrum fuer Tumordiagnostik und Praevention St. Gallen
Switzerland SpitalSTS AG Simmental-Thun-Saanenland Thun
Switzerland Kantonsspital Winterthur Winterthur
Switzerland Universitäts Spital Zürich Zürich

Sponsors (1)

Lead Sponsor Collaborator
Swiss Group for Clinical Cancer Research

Countries where clinical trial is conducted

France,  Germany,  Netherlands,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival (OS) - Analysis Population: ITT Population 1 Patients being alive 24 months after randomization. A success is considered if a patient is alive at least 24 months after randomization. Analysis Population: ITT Population 1 24 months
Secondary OS - Analysis Population: ITT Population 2 Proportion of patients being alive 24 months after randomization. A success is considered if a patient is alive at least 24 months after randomization. Analysis Population: ITT Population 2 24 months
Secondary Progression Free Survival (PFS) of first-line treatment ignoring first Central Nervous System (CNS) lesion PFS of first-line treatment ignoring first CNS lesion is the time from randomization to first event progression. A PFS of first-line treatment ignoring first CNS lesion event is defined as (whichever occurs first):
Disease progression (PD) after having received first-line treatment and prior to the next treatment
Death due to any reason Patients without events will be censored at last tumor assessment date without PFS ignoring first CNS lesion event during the first-line treatment period or prior to starting new treatment.
Analysis population: ITT Population 1
10 / 16 months (PFS will be calculated sustained from randomization until documented PD (ignoring first CNS lesion) or death, whichever occurs first during first-line treatment )
Secondary PFS of second-line treatment PFS of second-line treatment is the time from registration of second-line treatment to progression. A PFS event of second-line treatment is defined as (whichever occurs first):
Disease progression after having received second-line treatment and prior to the next treatment
PD CNS after having received first-line treatment and prior to the next treatment
Death due any reason during the second-line treatment period Patients without events will be censored at last tumor assessment date without PD and PD CNS during the second-line treatment period or prior to starting new treatment.
Analysis Population: ITT Population 2
8 months (PFS will be calculated sustained from registration of second line treatment until documented PD, PD CNS or death, whichever occurs first during second-line treatment)
Secondary PFS of second-line treatment ignoring first CNS lesion PFS of second-line treatment ignoring first CNS lesion is the time from registration of second-line treatment to the first event occurs. A PFS of second-line treatment ignoring first CNS lesion event is defined as (whichever occurs first):
Disease progression after having received second-line treatment and prior to the next treatment
Death due any reason during the second-line treatment period Patients without events will be censored at last tumor assessment date without PFS ignoring first CNS lesion event during the second-line treatment period or prior to starting new treatment.
Analysis Population: ITT Population 2
9 months (PFS will be calculated sustained from registration of second line treatment until documented PD (ignoring first CNS lesion) or death, whichever occurs first during second-line treatment)
Secondary Time to failure of strategy (TFS) of first- plus second-line treatment TFS of first plus second-line treatment is the time from randomization to TFS event occurs. A TFS event of first plus second-line treatment is defined as (whichever occurs first):
Disease progression after having received the first and second-line treatment and prior to the next treatment
PD CNS after having received first- and second-line treatment and prior to the next treatment
Death due to tumor prior to the third-line treatment Patients without events will be censored at last tumor assessment without PD and PD CNS during first and second-line treatment period or prior to starting new treatment.
Analysis Population: ITT Population 1
18 / 24 months (TFS will be calculated sustained from randomization until documented PD, PD CNS or death, whichever occurs first before starting third-line therapy )
Secondary Overall survival OS OS will be calculated from randomization until death. Patients still alive or lost of follow up are censored at their last date known alive.
Analysis Population: ITT Population 1
OS will be calculated from randomization until death (estimated median: 32 months)
Secondary Objective response (OR) of first-line treatment (based on investigator assessment) 10 / 16 months (OR is defined as the best status of response CR or PR up to first progression or start of a new treatment)
Secondary Disease control (DC) of first-line treatment (based on investigator assessment) 6 months (DC is defined as CR, PR or SD for 6 months after randomization and no PD at 6 month after randomization)
Secondary OR of second-line treatment (based on investigator assessment) 9 months (OR is defined as the best status of response CR or PR after registration for second-line treatment up to second progression or start of a new treatment)
Secondary DC of second-line treatment (based on investigator assessment) 6 months (DC is defined as the response CR, PR or SD for 6 months after registration of second-line treatment)
Secondary Adverse events (AEs) according to the NCI CTCAE v4.0 of first-line treatment Adverse events are assessed by the NCI CTCAE v4.0. from registration until registration of second-line treatment or start of follow-up (which occurs first). Throughout first-line treatment (estimated up to 16 months)
Secondary AEs according to the NCI CTCAE v4.0 of second-line treatment Adverse events are assessed by the NCI CTCAE v4.0.from second-line registration until PD or start of follow-up (which occurs first) plus 30 days. Throughout second-line treatment (estimated up to 9 months)
Secondary AEs grade =2 until first progression (ignoring first CNS lesion) Adverse events are assessed by Common terminology criteria for adverse events (CTCAE) v4.0. From randomization until first progression (documented PD, PD CNS or death) Throughout first-line treatment (estimated up to 16 months)
Secondary Quality of Life (QoL) At baseline and every 12 weeks (three-monthly) until progression or up to a maximum of 24 months during 1st line therapy. Within 3 weeks prior to registration, after 12 and 24 weeks during 2nd line therapy.
Secondary PFS of third-line treatment PFS will be calculated sustained from start of third-line treatment to progression (PD, PD CNS or death) 4 months
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2